Semaglutide's seven-day half-life means the medication remains active in your bloodstream for a full week, allowing a single weekly injection to maintain therapeutic levels
In families of patients with PA (pernicious anaemia), ulcerative colitis, rheumatoid arthritis, polymyalgia, psoriasis, sarcoidosis, lupus were in one study more common than in those of people without PA
The medication improves several aspects of health at the same time
The real question for cagrilintide isnt whether it beats tirzepatide solo, but whether its mechanism earns it a complementary role: either as part of a combination like CagriSema or as a standalone option for people who need something outside the GLP-1 family
vitamin D intake ~20% of recommendations Lean mass risk: protein + calcium insufficiency may contribute, alongside other drivers B-vitamins: thiamine and cobalamin deficits appear to increase over time Clinical takeaway (my approach): GLP-1s dont cause malnutrition in everyone but they can unmask risk in the wrong context (older adults, low-protein diets, restrictive eating patterns, prolonged nausea/vomiting, rapid weight loss, post-bariatric patients)
To test the system, I entered exaggerated numbers